Onco Actu du 15 mai 2017

	4.1 Dép., diag. & prono. - Prostate
Myriad Genetics' Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer [Myriad] Strong Predictive Power in Both African American and Non-African American Patients.
Myriad touts 10-year data for prostate cancer screen [FierceBiotech] The new study, which will be presented at the American Urological Association’s annual meeting, followed 767 men with localized prostate cancer, according to a statement. They underwent the Prolaris test to predict the risk of metastatic disease up to 10 years after diagnosis.
	4.2 Dép., diag. & prono. - Génome
New Gene Tests Pose a Threat to Insurers [NY Times] Increasing numbers of people at low risk might decide the insurance was not worth the rising price. Even many at high risk would eventually find the policies unaffordable. It is the definition of an insurance death spiral.
	5. Traitements
NCI ALMANAC: A New Tool for Research on Cancer Drug Combinations [NCI] This resource, called the NCI ALMANAC, provides data showing how well pairs of Food and Drug Administration-approved cancer drugs performed in killing tumor cells from the NCI-60 Human Tumor Cell Lines, a library of cancer cell lines maintained by NCI.
	5.12 Immunothérapies
Competition between immune cells could explain why some immunotherapy drugs fail [Cancer Research UK] “This study shows that to improve the next generation of immunotherapy treatments we need to know more about how these drugs interact with other immune cells that are found in tumours."
Turmoil in Immuno-oncology [in the Pipeline] The paper demonstrates transfer of the antibodies to macrophages taking place within a half hour, which is rather alarming. That’s the bad news. But the good news is that these antibodies are still showing efficacy anyway, and that this response might be greatly enhanced by blocking this macrophage transfer pathway.
	5.12.5 Immunothérapies - Pharma
AstraZeneca gains major I-O ground with Imfinzi lung cancer maintenance stunner [FiercePharma] If the company was to win global regulatory go-aheads in that population—and AZ said it is already engaged in “active discussion” with authorities about its submissions—the opportunity in the G7 markets would number 47,000 patients.
AstraZeneca Shows That With Immune Cancer Drugs, No One Knows What's Next [Forbes] The challenge for investors: the sales of these drugs are increasing much faster than our understanding of the science around them. By the time oncologists really understand how to use these potent new medicines, or to predict where they will work and where they won't, it will already be too late to place a bet.
AstraZeneca’s shares spike on a surprise coup in PhIII lung cancer data [EndPoints] This AstraZeneca trial wasn’t the big study analysts have been waiting for. AstraZeneca has been betting heavily on MYSTIC, using a combination of durvalumab and the CTLA-4 drug tremelimumab for NSCLC.
	5.2 Pharma
IMBRUVICA® (ibrutinib) Pooled Outcomes Data from Three Phase 3 Studies Suggest Potential Clinical Efficacy in Patients with High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [AbbVie] Results from data presented at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) further suggest that risk factors typically associated with poor clinical outcomes may be less relevant with ibrutinib treatment.
	5.2.1 Pharma - Partenariats
Clinigen partners with Tesaro’s PARP med for European preapproval access [FiercePharma] This also comes just a few weeks after Clinigen scored a similar pact with French pharma Onxeo to bring blood cancer med belinostat to European patients, again through a managed access program and before its approval.
	6.2 Implants mammaires
French court orders TÜV to pay damages for faulty breast implants [Reuters] The ruling confirmed a previous decision by the administrative court in the southern French city of Toulon, which ordered TÜV in January to pay 3,000 euros ($3,200) to each plaintiff in a giant class action case concerning 20,000 victims across 14 countries.
A Shocking Diagnosis: Breast Implants ‘Gave Me Cancer’ [NY Times] Nearly all the cases have been linked to implants with a textured or slightly roughened surface, rather than a smooth covering. Texturing may cause inflammation that leads to cancer. If detected early, the lymphoma is often curable.
What You Need to Know if You Have Breast Implants [NY Times] The Food and Drug Administration says women with implants who are not experiencing any problems with them should stick to routine care, and do not need to have the implants removed. But symptoms like breast pain, swelling, fluid buildup or lumps should not be ignored.
	6.3 Associations/Fondations
We ran a national cancer conference with two staff [The Guardian] We found that organising a conference is more work than you’d think. I thought it would just be a case of finding a date and a venue, getting the speakers and pulling in the participants, but there are always things you don’t foresee that take up a lot of time. Here’s what we learned.
	6.7 DMP, Big Data & applis
If You Still Use Windows XP, Prepare For the Worst [Wired] The natural question, given the absurd level of risk that comes with running Windows XP in 2017, is why on earth would anyone stick with it, much less millions of people and companies with so much to lose.
The Ransomware Meltdown Experts Warned About Is Here [Wired] Hospitals make for popular ransomware victims because they have an urgent need to restore service for their patients. They may therefore be more likely to pay criminals to reinstate systems. They also often make for relatively easy targets.
Jeremy Hunt 'ignored warning signs' before cyber-attack hit NHS [The Guardian] Shadow health secretary says concerns were repeatedly flagged about outdated computer systems that are vulnerable to attack.